Given that HER2 IHC 3+ or HER2 amplification by FISH is very rare in lung cancers, clinical trials evaluating the activity of trastuzumab in lung cancers with lower levels of HER2 IHC positivity have been negative [126,127]. The gene discussed is ERBB2; the disease is lung cancer.